AutoCyte.
This article was originally published in The Gray Sheet
Executive Summary
Submits an amendment to its June 1997 premarket approval application for use of its Prep sample preparation system in cervical cancer screening. The amendment follows a request by FDA for more information, including additional analysis and presentation of existing clinical data, to demonstrate sensitivity to low grade, high grade, and cancerous lesions, the firm states. A "small nonclinical internal study" also was included in the amendment. The PMA will not need to be reviewed by an agency advisory panel ("The Gray Sheet" July 14, 1997, p. 8)...
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.